ArticleBMC cancer2025

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.

Wei Fan Sui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.